Antiviral agents for influenza: a comparison of cost-effectiveness data (Q33226840)

24 July 2017

1 reference

title

Antiviral agents for influenza: a comparison of cost-effectiveness data (English)

1 reference

24 July 2017

Larry D Lynd

1

1 reference

24 July 2017

Ron Goeree

series ordinal

2

1 reference

24 July 2017

Bernie J O'Brien

series ordinal

3

1 reference

24 July 2017

publication date

1 January 2005

1 reference

24 July 2017

1 reference

24 July 2017

volume

23

1 reference

24 July 2017

issue

11

1 reference

24 July 2017

page(s)

1083-1106

1 reference

Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections

24 July 2017

cites work

1 reference

12 December 2020

Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group

1 reference

12 December 2020

The impact of influenza and influenza-like illness on productivity and healthcare resource utilization in a working population

1 reference

12 December 2020

Economic evaluation of strategies for the control and management of influenza in Europe

1 reference

12 December 2020

Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group.

1 reference

12 December 2020

The treatment of influenza with antiviral drugs

1 reference

12 December 2020

Economic analysis of influenza vaccination and antiviral treatment for healthy working adults

1 reference

12 December 2020

Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group

1 reference

12 December 2020

Clinical signs and symptoms predicting influenza infection

1 reference

12 December 2020

Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP)

1 reference

12 December 2020

Cost-effectiveness of vaccination versus treatment of influenza in healthy adolescents and adults

1 reference

12 December 2020

Presentation with influenza-like illness in general practice: implications for use of neuraminidase inhibitors

1 reference

12 December 2020

Evaluation of Clinical Case Definitions of Influenza: Detailed Investigation of Patients During the 1995‐1996 Epidemic in France

1 reference

12 December 2020

Impact of zanamivir treatment on productivity, health status and healthcare resource use in patients with influenza. Zanamivir Study Group

1 reference

12 December 2020

The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial

1 reference

12 December 2020

Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment

1 reference

12 December 2020

Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial

1 reference

12 December 2020

Advances in influenza virus vaccine research

1 reference

12 December 2020

Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group.

1 reference

12 December 2020

Diagnostic testing or empirical neuraminidase inhibitor therapy for patients with influenza-like illness: what a difference a day makes

1 reference

12 December 2020

Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study

1 reference

12 December 2020

Global epidemiology of influenza: past and present.

1 reference

12 December 2020

The Effectiveness of Vaccination against Influenza in Healthy, Working Adults

1 reference

12 December 2020

The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community

1 reference

12 December 2020

Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza

1 reference

12 December 2020

Estimates of the US health impact of influenza

1 reference

12 December 2020

Bedside rapid flu test and zanamivir prescription in healthy working adults: a cost-benefit analysis

1 reference

12 December 2020

Management of Influenza in Adults Older than 65 Years of Age: Cost-Effectiveness of Rapid Testing and Antiviral Therapy

1 reference

12 December 2020

Influenza burden of illness: estimates from a national prospective survey of household contacts in France.

1 reference

12 December 2020

Oseltamivir for treatment of influenza in healthy adults: pooled trial evidence and cost-effectiveness model for Canada

1 reference

12 December 2020

Neuraminidase inhibitors for preventing and treating influenza in healthy adults.

1 reference

12 December 2020

Cost effectiveness of zanamivir for the treatment of influenza in a high risk population in Australia

1 reference

12 December 2020

Cost-effectiveness of newer treatment strategies for influenza

1 reference

12 December 2020

The impact of influenza epidemics on hospitalizations.

1 reference

12 December 2020

Influenza virus neuraminidase inhibitors

1 reference

12 December 2020

Clinical efficacy and safety of the selective oral neuraminidase inhibitor oseltamivir in treating acute influenza--placebo-controlled double-blind multicenter phase III trial

1 reference

12 December 2020

Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP)

1 reference

12 December 2020

French economic evaluations of influenza and influenza vaccination

1 reference

12 December 2020

Prevention and early treatment of influenza in healthy adults

1 reference

12 December 2020

Influenza vaccines. A reappraisal of their use.

1 reference

12 December 2020

Cost-effectiveness analysis of inhaled zanamivir in the treatment of influenza A and B in high-risk patients

1 reference

12 December 2020

Influenza. The role of burden-of-illness research

1 reference

12 December 2020

The economic impact of pandemic influenza in the United States: priorities for intervention.

1 reference

12 December 2020

Influenza and pneumococcal vaccination levels among persons aged > or = 65 years--United States, 1999.

1 reference

12 December 2020

Economic impact of influenza. The individual's perspective

1 reference

12 December 2020

Treat or test first? Decision analysis of empirical antiviral treatment of influenza virus infection versus treatment based on rapid test results.

1 reference

12 December 2020

Effective protection against influenza after vaccination with subunit vaccine

1 reference

12 December 2020

Zanamivir for the treatment of influenza in adults: a systematic review and economic evaluation

1 reference

12 December 2020

Cost-effectiveness of the influenza vaccine in a healthy, working-age population

1 reference

12 December 2020

Do neuraminidase inhibitors prevent influenza?

1 reference

12 December 2020

10.2165/00019053-200523110-00003

Identifiers

DOI

1 reference

Dimensions Publication ID

24 July 2017

1041170296

0 references

1 reference